Category Archives: Nano medicine

Medical technologies like smart pills, vaccines personalization, and more are opening newer ways for cancer treatment.

FREMONT, CA: Treatment options for cancer have massively evolved and improved in recent years. Today, care providers continue to explore new possibilities for cancer treatment with the help of advanced technologies. Treatments like radiation therapy, personalization of cancer vaccines, and nano-medicines, experience rapid adoptions by care providers for cancer treatment.

1. Radiation Therapy

Health care providers use radiation therapy, highly effective cancer treatment. This treatment aims accurately and directly at the cancer cells, resulting in the killing or reduction of the tumor-affected cells and tissues in the patients. The high-energy rays prove to be highly effective in reducing the risk of cancer and recurrence of common cancer, such as breast cancer, bowel cancer, and prostate cancer, and helps the surgeons remove or kill the cancer-affected tissues. The latest medical technologies for cancer integrated with radiation therapy are making the treatments more quick, accurate, and effective.

2. Ingestible Sensors and Smart Pills

Ingestible technology in the healthcare field is used to help the patients manage their medications. The new technology allows the care providers to ensure their cancer patients are taking medications as prescribed. Ingestible sensors offer close monitoring of patients' health conditions, which include sensing the growth of tumors and instantly guiding the smart pills towards precise tumor locations and heart rate, activity level, and sleep cycle of the patients. The digital pills enable real-time transmission of health information to a small patch on the patients' skin, which can be connected to a mobile app that both the patients and their doctors can access.

3. Personalized Cancer Vaccines

Developments in personalized cancer vaccines enable the next-generation cancer treatment method. The advanced vaccine is used with the computational pipeline, which can precisely identify tumor-unique mutations and successfully induce immune responses in cancer patients, helping them fight their diseases. The technique follows cell-based immune therapies that provide the patients with tumor-attacking T cells, and the delivered neo-antigens in the patients body create vaccines to stimulate the T cells. The advanced vaccines are given in the form of messenger RNA that produces a particular protein according to the patients physiological requirements.

4. Nano-Medicines

The innovative and promising technology, nano-medicine provides many advantages over conventional cancer therapies and new opportunities for early detection, improved treatment, and diagnosis of cancer. The benefits of nano-medicines for cancer treatment attract care providers, as the unique physical, chemical, mechanical, and optical properties of these medicines are easier to access with more efficiency. The innovative medicine uses nano-carriers to deliver therapeutic molecules, such as drugs, proteins, or nucleic acids. The nano-structures for the cancer treatment can also be exploited to favor the delivery of immune agents and represent therapeutic tool.

Technology leads the cancer treatment sector towards a bright future, where the increasing advantages of innovative cancer treatment solutions can be accessed easily across the world. Nanotechnology, targeted radiation, personalized vaccines are revolutionizing the medical technology industry, promising the possibilities of more solutions that can successfully fight cancer and prevent its reoccurrence. The ever-evolving field of cancer treatments consistently puts effort into exploring innovative diagnostics and treatments, leading to more creative solutions like molecular cancer diagnostics, identify genetic and lifestyle causes of diseases, and perform precision surgery.

See more here:
4 Innovative Solutions Fostering Advanced Cancer Treatment - Medical Tech Outlook

While many people love colorful photos of landscapes, flowers or rainbows, some biomedical researchers treasure vivid images on a much smaller scale as tiny as one-thousandth the width of a human hair.

To study the micro world and help advance medical knowledge and treatments, these scientists use fluorescent nano-sized particles.

Quantum dots are one type of nanoparticle, more commonly known for their use in TV screens. Theyre super tiny crystals that can transport electrons. When UV light hits these semiconducting particles, they can emit light of various colors.

That fluorescence allows scientists to use them to study hidden or otherwise cryptic parts of cells, organs and other structures.

Im part of a group of nanotechnology and neuroscience researchers at the University of Washington investigatinghow quantum dots behave in the brain.

Common brain diseases are estimated to cost the U.S.nearly US$800 billionannually. These diseases including Alzheimers disease and neurodevelopmental disorders are hard to diagnose or treat.

Nanoscale tools, such as quantum dots, that can capture the nuance in complicated cell activities hold promise as brain-imaging tools or drug delivery carriers for the brain. But because there are many reasons to be concerned about their use in medicine, mainly related to health and safety, its important to figure out more about how they work in biological systems.

Researchers firstdiscovered quantum dots in the 1980s. These tiny particles are different from other crystals in that they can produce different colors depending on their size. They are so small that that they are sometimes called zero-dimensional or artificial atoms.

The most commonly known use of quantum dots nowadays may be TV screens. Samsung launched theirQLED TVs in 2015, and a few other companies followed not long after. But scientists have been eyeing quantum dots for almost a decade. Because of their unique optical properties they can produce thousands of bright, sharp fluorescent colors scientists started using them as optical sensors or imaging probes, particularly in medical research.

Scientists have long used various dyes to tag cells, organs and other tissues to view the inner workings of the body, whether that be for diagnosis or for fundamental research.

The most common dyes have some significant problems. For one, their color often cannot survive very long in cells or tissues.They may fade in a matter of seconds or minutes. For some types of research, such as tracking cell behaviors or delivering drugs in the body, these organic dyes simply do not last long enough.

Quantum dots would solve those problems. They are very bright and fade very slowly.Their color can still stand out after a month. Moreover, they are too small to physically affect the movement of cells or molecules.

Those properties make quantum dots popular in medical research. Nowadays quantum dots are mainly used for high resolution 3D imaging of cells or molecules, or real-time tracking probes inside or outside of animal bodies that can last for an extended period.

But their use is still restricted to animal research, because scientists areconcerned about their use in human beings. Quantum dots commonly contain cadmium, a heavy metal that is highly poisonous and carcinogenic. They mayleak the toxic metalor form an unstable aggregate, causing cell death andinflammation. Some organs may tolerate a small amount of this, but the brain cannot withstand such injury.

My colleagues and I believe an important first step toward wider use of quantum dots in medicine is understanding how they behave in biological environments. That could help scientists design quantum dots suitable for medical research and diagnostics: When theyre injected into the body, they need to stay small particles, be not very toxic and able to target specific types of cells.

We looked at thestability, toxicity and cellular interactions of quantum dots in the developing brains of rats. We wrapped the tiny quantum dots in different chemical coats. Scientists believe these coats, with their various chemical properties, control the way quantum dots interact with the biological environment that surrounds them. Then we evaluated how quantum dots performed in three commonly used brain-related models: cell cultures, rat brain slices and individual live rats.

We found that different chemical coats give quantum dots different behaviors. Quantum dots with a polymer coat of polyethylene glycol (PEG) were the most promising. They are more stable and less toxic in the rat brain, and at a certain dose dont kill cells. It turns out that PEG-coated quantum dots activate a biological pathway that ramps up the production of a molecule that detoxifies metal. Its a protective mechanism embedded in the cells that happens to ward off injury by quantum dots.

Quantum dots are also eaten bymicroglia, the brains inner immune cells. These cells regulate inflammation in the brain and are involved in multiple brain disorders. Quantum dots are then transported to the microglias lysosomes, the cells garbage cans, for degradation.

But we also discovered that the behaviors of quantum dots vary slightly between cell cultures, brain slices and living animals. The simplified models may demonstrate how a part of the brain responds, but they are not a substitute for the entire organ.

For example, cell cultures contain brain cells but lack the connected cellular networks that tissues have. Brain slices have more structure than cell cultures, but they also lack the full organs blood-brain barrier its Great Wall that prevents foreign objects from entering.

Our results offer a warning: Nanomedicine research in the brain makes no sense without carefully considering the organs complexity.

That said, we think our findings can help researchers design quantum dots that are more suitable for use in living brains. For example, our research shows that PEG-coated quantum dots remain stable and relatively nontoxic in living brain tissue while having great imaging performance. We imagine they could be used to track real-time movements of viruses or cells in the brain.

In the future, along with MRI or CT scans, quantum dots may become vital imaging tools. They might also be used as traceable carriers that deliver drugs to specific cells. Ultimately, though, for quantum dots to realize their biomedical potential beyond research, scientists must address health and safety concerns.

Although theres a long way to go, my colleagues and I hope the future for quantum dots may be as bright and colorful as the artificial atoms themselves.

Continue reading here:
Quantum dots that light up TVs could be used for brain research - Stuff Magazines

Nanorobotic is a new technology of robot engineering. The development of nano-robot belongs to molecular nanotechnology

Nanorobotic Marketreport offers a comprehensive valuation of the marketplace. It does so via in-depth comprehensions, grateful market growth by pursuing past developments, and studying the present situation and future forecasts based on progressive and likely areas. Each research report supports as a depository of analysis and data for each and every side of the industry, including but not limited to: Regional markets, types, applications, technology developments and the competitive landscape.

The Nanorobotic Market report profiles the following companies, which includes: Bruker, Jeol, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging

Get Sample Copy of this Report at @https://www.reportsintellect.com/sample-request/581106

Report Description:-

This report presents a comprehensive overview, market shares and growth opportunities of Nanorobotic market by product type, application, key companies and key regions.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Product Type Coverage:-Nanomanipulator, Bio-Nanorobotic, Magnetically Guided Robot

Product Application Coverage:-Nanometer Medicine, Biomedical, Machine, Other

Market Segment by Regions, regional analysis coversNorth America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Get 10% Discount on ThisReport@https://www.reportsintellect.com/discount-request/581106

Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Nanorobotic- Market Size2.2 Nanorobotic- Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Nanorobotic- Market Size by Manufacturers3.2 Nanorobotic- Key Players Head office and Area Served3.3 Key Players Nanorobotic- Product/Solution/Service3.4 Date of Enter into Nanorobotic- Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Nanorobotic- Sales by Product4.2 Global Nanorobotic- Revenue by Product4.3 Nanorobotic- Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Nanorobotic- Breakdown Data by End User

Research objectives

About Us:-Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

Sales@reportsintellect.comPH + 1-706-996-2927US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

More here:
Nanorobotic Market 2019 Technological Perspective, Latest Trends and key manufacturers:: Bruker, Jeol, Thermo Fisher Scientific, Ginkgo Bioworks -...

Marine Le Goas,1 Marie Paquet,25 Aurlie Paquirissamy,1 Julien Guglielmi,24 Cathy Compin,24 Juliette Thariat,6 Georges Vassaux,24 Valrie Geertsen,1 Olivier Humbert,25 Jean-Philippe Renault,1 Graldine Carrot,1 Thierry Pourcher,24 Batrice Cambien24

1NIMBE, Commissariat lEnergie Atomique, Centre National Recherche Scientifique UMR 3685, Universit Paris-Saclay, Gif-sur-Yvette, France; 2Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Institut de Biosciences et Biotechnologies dAix-Marseille (BIAM), Commissariat lEnergie Atomique, Nice, France; 3Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), University Nice Sophia Antipolis, Nice, France; 4Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), University Cte dAzur, Nice, France; 5Nuclear Medicine Department, Centre Antoine Lacassagne, Nice, France; 6Department of Radiation Oncology, Centre Franois Baclesse, Universit de Normandie, Caen, France

Correspondence: Batrice CambienLaboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), University Nice Sophia Antipolis, 28 Avenue Valombrose, Nice Cedex 2 06107, FranceTel +33 493 377 715Email cambien@unice.fr

Background: Human trials combining external radiotherapy (RT) and metallic nanoparticles are currently underway in cancer patients. For internal RT, in which a radioisotope such as radioiodine is systemically administered into patients, there is also a need for enhancing treatment efficacy, decreasing radiation-induced side effects and overcoming radio-resistance. However, if strategies vectorising radioiodine through nanocarriers have been documented, sensitizing the neoplasm through the use of nanotherapeutics easily translatable to the clinic in combination with the standard systemic radioiodine treatment has not been assessed yet.Method and materials: The present study explored the potential of hybrid poly(methacrylic acid)-grafted gold nanoparticles to improve the performances of systemic 131I-mediated RT on cancer cells and in tumor-bearing mice. Such nanoparticles were chosen based on their ability previously described by our group to safely withstand irradiation doses while exhibiting good biocompatibility and enhanced cellular uptake.Results: In vitro clonogenic assays performed on melanoma and colorectal cancer cells showed that poly(methacrylic acid)-grafted gold nanoparticles (PMAA-AuNPs) could efficiently lead to a marked tumor cell mortality when combined to a low activity of radioiodine, which alone appeared to be essentially ineffective on tumor cells. In vivo, tumor enrichment with PMAA-AuNPs significantly enhanced the killing potential of a systemic radioiodine treatment.Conclusion: This is the first report of a simple and reliable nanomedicine-based approach to reduce the dose of radioiodine required to reach curability. In addition, these results open up novel perspectives for using high-Z metallic NPs in additional molecular radiation therapy demonstrating heterogeneous dose distributions.

Keywords: internal radioisotope therapy, radioiodine, polymer-grafted gold nanoparticles, melanoma, colorectal cancer, radio-enhancement

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Link:
Improving 131I Radioiodine Therapy By Hybrid Polymer-Grafted Gold Nano | IJN - Dove Medical Press

Han Liao,1,2 Shan Zhao,1,2 Huihui Wang,1,2 Yang Liu,1 Ying Zhang,1 Guangwei Sun1

1Scientific Research Center for Translational Medicine, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, Peoples Republic of China; 2University of Chinese Academy of Sciences, Beijing 100049, Peoples Republic of China

Correspondence: Guangwei SunScientific Research Center for Translational Medicine, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, Peoples Republic of ChinaTel/Fax +86-411-82463027Email sungw@dicp.ac.cn

Background: Amphiphilic fusion drugs are covalent conjugates of a lipophilic drug and a hydrophilic drug or their active fragments. These carrier-free self-assembly nanomaterials are helpful to co-deliver two synergic drugs to the same site regardless of pharmacokinetic properties of individual drugs. Retinoic hydroxamic acid (RHA) is a fusion drug of all-trans retinoic acid (ATRA) and vorinostat, a histone deacetylase (HDAC) inhibitor showing synergic effect with ATRA on cancer therapy. Although RHA was synthesized in 2005, its nanoscale self-assembly property, anticancer activity, and possible related mechanism are still unclear.Methods: RHA nanoparticles were observed under transmission electron microscope (TEM). Both in vitro cell viability, colony formation assay, and in vivo xenograft mouse tumor model were employed here to study anticancer activity of RHA nanoparticles. The putative synergic anticancer mechanism of activating retinoic acid receptor (RAR) and inhibiting HDAC were investigated via receptor inhibitor rescue assay and in vitro enzyme activity assay, respectively.Results: RHA could form nanoparticle formation by self-assembly and abrogates growth of several solid tumor cell lines even after RHA nanoparticles washout. However, opposite to our initial hypothesis, pre-treating the melanoma cells with RAR antagonists showed no impact on inhibitory effect of RHA nanoparticles, which suggested that the target of the molecule on melanoma cells is not RAR and retinoid X receptor (RXR). Importantly, RHA nanoparticles inhibited the growth of xenograft tumors without obvious impact on haematological indexes and hepatorenal function of these tumor-bearing mice.Conclusion: Our findings demonstrate the promise of RHA nanoparticles in treating malignant melanoma tumors with high efficacy and low toxicity.

Keywords: nano-drugs, self-assembly, retinoid, cancer therapy, melanoma

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy | IJN - Dove Medical Press

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/6370

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Request to Browse Full Table of Content, figure and Tables @https://www.persistencemarketresearch.com/toc/6370

Key geographies evaluated in this report are:

Key features of this report

See the original post here:
Healthcare Nanotechnology Nanomedicine Market to Witness a Pronounce Growth During 2019-2029 - Zebvo

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/6370?source=atm

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Request to View TOC at https://www.persistencemarketresearch.com/toc/6370?source=atm

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are: North America U.S Canada Europe France, Germany, Italy, Spain, and the UK Eastern Europe CIS APAC China India Japan Australia Others Latin America Argentina Brazil Others

Key features of this report Drivers, restraints, and challenges shaping the Healthcare Nanotechnology (Nanomedicine) market dynamics Latest innovations and key events in the industry Analysis of business strategies of the top players Healthcare Nanotechnology (Nanomedicine) market estimates and forecasts(2015 -2021)

Get Full Report Access of this report at https://www.persistencemarketresearch.com/checkout/6370?source=atm

View post:
Healthcare Nanotechnology (Nanomedicine) Market Likely To Experience High Revenue Generation In The Forthcoming Years - Commerce Gazette

Indian scientists have found that BCG the worlds only vaccine against TB can be made more effective if nano-particles of curcumin, the main component of the popular kitchen spice turmeric are used in tandem with the shot.

The discovery, scientists say, open up a new window to tackle drug-resistant tuberculosis, one of the worlds biggest public health threats that kills lakhs each year.

Biologists at Jawaharlal Nehru University, Delhi were looking for ways to improve the existing treatment options for TB when they turned their attention to nano-curcumin, an ultra-small version of the wonder chemical that lies at the core of the kitchen spice, known to harbour many medicinal properties.

"We have shown that a booster dose of BCG together with nano-curcumin gives superior vaccine efficacy. This opens up a new area of vaccine research and has huge implications. We are ready for clinical trials," team leader Gobardhan Das from JNU's Special Centre for Molecular Medicine told DH.

Discovered in 1921, BCG is the world's sole TB vaccine, but it only protects children and that too with varying efficacy.

In their experiments aimed at enhancing the vaccines efficiency, the researchers first injected laboratory mice with BCG vaccine and subsequently gave them nano-curcumin shots for 30 days.

The JNU team collaborated with KITT University, Bhubaneswar and Vanderbilt University, Tennessee, the USA to source the nano-curcumin and analyzing the results.

When they measure biochemical parameters to examine the immune responses, they found an improvement in the vaccines efficacy. Nanocurcumin not only creates an environment conducive for priming and activating the cells that fight against the enemy but also enhances the production of two key immune cells that battle with the bacteria.

Curcumin nanoparticles hold promise for enhancing the efficacy of TB vaccines, the team reported in Infection and Immunity, a journal published by American Society for Microbiology.

"This is a significant result with the potential to address a critical unmet need in TB vaccine development, especially when an alternative to BCG vaccine is nowhere on the horizon," said Anand Ranganathan, a JNU scientist and one of the members of the team.

A vaccine candidate that imparts better protection by BCG would mean fewer antibiotics are required, hence would minimize the chances of development of drug-resistance. This study demonstrates that curcumin nano-particles holds promise to enhance the efficacy of BCG vaccines but more experiments are required to further evaluate its safety and efficacy in other animal models, commented Ramandeep Singh, from Translational Health Science and Technology Institute, Faridabad, who researches on TB but not associated with the BCG paper.

With nearly 28 lakh cases, India has the world's highest number of TB cases in 2016 even though the researchers fear that there are lakhs who escape the surveillance net. The infectious disease causes one death every 90 seconds and 12 lakh new infections each year besides an economic burden of nearly $ 340 billion between 2006 and 2014.

See the article here:
TB vaccines with nano-curcumin work wonders - Deccan Herald

Indian scientists have shown that turmerics yellow ingredient may help enhance the efficacy of the lone standard vaccine against tuberculosis, which is given to all children at birth but is effective only for about a decade.

Researchers at Jawaharlal Nehru University, New Delhi, have carried out studies on mice to demonstrate that curcumin - a molecule extracted from turmeric when encapsulated into tiny nano-particles, can increase the efficacy of the bacille Camille-Guerin (BCG) vaccine.

The protective effect of the BCG vaccine diminishes over time and is lost by the time children turn 10 or 12.

Gobardhan Das, head of the Centre for Molecular Medicine at JNU, and his colleagues have now shown that curcumin nano-particles can enhance the capacity of the BCG vaccine to stimulate the long-term memory of the immune system.

They found that the efficacy of the BCG vaccine was stronger and lasted longer in immunised mice that had also received curcumin nano-particles for 30 days after receiving the vaccines.

They have published their findings in the research journal Infection and Immunity.

When the immunised mice were challenged by a virulent strain of tuberculosis, delivered through aerosols, the bacterial loads in the lungs and spleen were significantly lower in the mice that had also received the curcumin nano-particles.

The JNU studies suggest that the addition of curcumin nano-particles activates two types of cells in the immune system, called Th1 and Th17, which play a key role in the long-term protection against tuberculosis infections.

We need to validate these findings, but if these results are extrapolated to humans, were proposing enhancing the efficacy of, and long-term protection with, BCG vaccines, Das said.

Earlier studies had established that curcumin can influence the immune system in animals and humans.

Our results suggest that nano-curcumin can elongate or stretch the ability of the immune system to recognise the TB bacilli, said Anand Ranganathan, a study team member.

Read more here:
Curcumin hope in TB fight - Telegraph India

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/6370?source=atm

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Request Report Methodology at https://www.persistencemarketresearch.com/methodology/6370?source=atm

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are: North America U.S Canada Europe France, Germany, Italy, Spain, and the UK Eastern Europe CIS APAC China India Japan Australia Others Latin America Argentina Brazil Others

Key features of this report Drivers, restraints, and challenges shaping the Healthcare Nanotechnology (Nanomedicine) market dynamics Latest innovations and key events in the industry Analysis of business strategies of the top players Healthcare Nanotechnology (Nanomedicine) market estimates and forecasts(2015 -2021)

Request to view TOC at https://www.persistencemarketresearch.com/toc/6370?source=atm

Read the original here:
Healthcare Nanotechnology (Nanomedicine) Market to Witness Growth Acceleration During 2015 2021 - Trading Herald